https://orcid.org/0000-0002-6383-3777
References
- Siegel RL , MillerKD, JemalA. Cancer statistics, 2017. CA Cancer J. Clin.67(1), 7–30 (2017).
- Einhorn LH , DonohueJ. Cis-diamminedi-chloroplatinum, vinblastine, and bleomycin combination therapy in disseminated testicular cancer. Ann. Intern. Med.87, 293–298 (1977).
- Cheng L , AlbersP, BerneyDMet al. Testicular cancer. Nat. Rev. Dis. Primers4(1), 29 (2018).
- Murphy BR , BreedenES, DonohueJPet al. Surgicalsalvage of chemorefractory germ cell tumors. J. Clin. Oncol.11(2), 324–329 (1993).
- Kondagunta GV , BaciKJ, DonadioAet al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J. Clin. Oncol.23(7), 6549–6555 (2005).
- Loehrer PJ Sr , LauerR, RothBJet al. Salvage therapy in recurrent germ cell tumor: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann. Intern. Med.109(7), 540–546 (1988).
- International Prognostic Factors Study Group , LorchA, BeyerJet al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J. Clin. Oncol.28(33), 4906–4911 (2010).
- Albany C , AdraN, SnavelyACet al. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. Ann. Oncol.29(2), 341–346 (2018).
- McCaffrey JA , MazumdarM, BajorinDFet al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J. Clin. Oncol.15(7), 2559–2563 (1997).
- Loehrer PJ Sr , GoninR, NicholsCRet al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J. Clin. Oncol.16(7), 2500–2504 (1998).
- Nichols CR , TricotG, WilliamsSDet al. Dose-intensive chemotherapy in refractory germ cell cancer – a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. Clin. Oncol.7(7), 932–939 (1989).
- Einhorn LH , WilliamsSD, ChamnessAet al. High-dose chemotherapy and stem-cell rescue for germ-cell tumors. N. Engl. J. Med.357(4), 340–348 (2007).
- Adra N , AbonourR, AlthouseSKet al. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: the Indiana University Experience. J. Clin. Oncol.35(10), 1096–1102 (2017).
- Kalra M , AdraN, McKayJet al. High-dose chemotherapy (HDCT) plus peripheral-blood stem cell transplant (PBSCT) for patients (pts) with relapsed germ-cell tumors (GCT) and active brain metastases (mets). J. Clin. Oncol.35(Suppl. 15), 4558 (2017).
- Feldman DR , SheinfeldJ, BajorinDFet al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J. Clin. Oncol.28, 1706–1713 (2010).
- Lorch A , KleinhansA, KramarAet al. Sequential versus single high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J. Clin. Oncol.30(8), 800–805 (2012).
- Beyer J , StenningS, GerlA, FossaS, SiegertW. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann. Oncol.13(4), 599–605 (2002).
- Pico JL , RostiG, KramarAet al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann. Oncol.16(7), 1152–1159 (2005).
- Lorch A , Bascoul-MolleviC, KramarAet al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J. Clin. Oncol.29(16), 2178–2184 (2011).
- Kilari D , D’SouzaA, FraserRet al. Autologous hematopoietic stem cell transplantation for male germ cell tumors: improved outcomes over 3 decades. Biol. Blood Marrow Transplant.25(6), 1099–1106 (2019).